Two of the World Health Organization’s (WHO) cannabis scheduling recommendations might face an uphill battle getting adopted later this year by the United Nations’ Commission on Narcotic Drugs (CND).
That revelation stems from an analysis of statements made by U.N.-member states at a recent two-day CND meeting. Still, many in the cannabis industry are hoping for a positive outcome at the end of the year, when a vote is planned.
The reason: If the two recommendations discussed at the CND meeting in June are approved, international trade in certain CBD preparations is expected to become more free.
That’s because such products would be subject to fewer international controls. And that, in turn, could boost sales.
During the recent closed-door CND meeting, participants discussed two of the WHO’s six cannabis-related recommendations:
- Recommendation 5.4 to delete cannabis “extracts and tinctures” from Schedule 1 of the 1961 Single Convention on Narcotics Drugs.
- Recommendation 5.5 to add a footnote to the cannabis entry in Schedule 1 of the 1961 Single Convention to clarify that preparations containing predominantly CBD and up to 0.2% THC are not under international control.